{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:36:48Z","timestamp":1793929008962,"version":"4.8.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.3816\/cbc.2009.s.008","type":"journal-article","created":{"date-parts":[[2009,8,19]],"date-time":"2009-08-19T21:04:30Z","timestamp":1250715870000},"page":"S73-S81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":509,"special_numbering":"S2","title":["Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer"],"prefix":"10.3816","volume":"9","author":[{"given":"Carey K.","family":"Anders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2009.s.008_bib1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.3816\/CBC.2009.s.008_bib2","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CBC.2009.s.008_bib3","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1073\/pnas.0932692100","article-title":"Repeated observation of breast tumor subtypes in independent gene expression data sets","volume":"100","author":"S\u00f8rlie","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CBC.2009.s.008_bib4","unstructured":"Swain SM. Triple-negative breast cancer: metastatic risk and role of platinum agents. Paper presented at: 44th Annual Meeting of the American Society of Clinical Oncology; May 30-June 3, 2008; Chicago, IL."},{"key":"10.3816\/CBC.2009.s.008_bib5","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","article-title":"Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma","volume":"10","author":"Nielsen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2009.s.008_bib6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/modpathol.3800528","article-title":"Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma","volume":"19","author":"Livasy","year":"2006","journal-title":"Mod Pathol"},{"key":"10.3816\/CBC.2009.s.008_bib7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ijc.23518","article-title":"How basal are triple-negative breast cancers?","volume":"123","author":"Bertucci","year":"2008","journal-title":"Int J Cancer"},{"key":"10.3816\/CBC.2009.s.008_bib8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(07)70074-8","article-title":"Triple-negative breast cancer: therapeutic options","volume":"8","author":"Cleator","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.3816\/CBC.2009.s.008_bib9","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/bcr1771","article-title":"Gene expression profiling and histopathological characterization of triple-negative\/basal-like breast carcinomas","volume":"9","author":"Kreike","year":"2007","journal-title":"Breast Cancer"},{"key":"10.3816\/CBC.2009.s.008_bib10","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","article-title":"Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study","volume":"295","author":"Carey","year":"2006","journal-title":"JAMA"},{"key":"10.3816\/CBC.2009.s.008_bib11","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s00428-005-0010-7","article-title":"p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas","volume":"447","author":"Matos","year":"2005","journal-title":"Virchows Arch"},{"key":"10.3816\/CBC.2009.s.008_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nrc726","article-title":"Modifiers of risk of hereditary breast and ovarian cancer","volume":"2","author":"Narod","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.3816\/CBC.2009.s.008_bib13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc1431","article-title":"BRCA1 and BRCA2: 1994 and beyond","volume":"4","author":"Narod","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.3816\/CBC.2009.s.008_bib14","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1158\/1078-0432.CCR-04-2064","article-title":"Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer","volume":"11","author":"Arnes","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2009.s.008_bib15","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/jnci\/djg050","article-title":"Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer","volume":"95","author":"Foulkes","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2009.s.008_bib16","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/modpathol.3800456","article-title":"Cytokeratin 5\/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors","volume":"18","author":"Laakso","year":"2005","journal-title":"Mod Pathol"},{"key":"10.3816\/CBC.2009.s.008_bib17","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1158\/1078-0432.CCR-04-2424","article-title":"Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype","volume":"11","author":"Lakhani","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2009.s.008_bib18","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.22618","article-title":"Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry","volume":"109","author":"Bauer","year":"2007","journal-title":"Cancer"},{"key":"10.3816\/CBC.2009.s.008_bib19","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/cncr.22836","article-title":"Differences in breast carcinoma characteristics in newly diagnosed African\u2013American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database","volume":"110","author":"Morris","year":"2007","journal-title":"Cancer"},{"key":"10.3816\/CBC.2009.s.008_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10549-007-9632-6","article-title":"Epidemiology of basal-like breast cancer [published erratum in: Breast Cancer Res Treat 2008; 109:141]","volume":"109","author":"Millikan","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2009.s.008_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1158\/1055-9965.EPI-06-0806","article-title":"Differences in risk factors for breast cancer molecular subtypes in a population-based study","volume":"16","author":"Yang","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.3816\/CBC.2009.s.008_bib22","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2009.s.008_bib23","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1158\/1055-9965.EPI-04-0394","article-title":"A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors","volume":"14","author":"Collett","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.3816\/CBC.2009.s.008_bib24","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2009.s.008_bib25","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/0008-5472.CAN-07-5644","article-title":"Subtypes of breast cancer show preferential site of relapse","volume":"68","author":"Smid","year":"2008","journal-title":"Cancer Res"},{"issue":"15 suppl","key":"10.3816\/CBC.2009.s.008_bib26","first-page":"43s","article-title":"Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors","volume":"26","author":"Heitz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2009.s.008_bib27","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/cncr.23930","article-title":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases","volume":"113","author":"Lin","year":"2008","journal-title":"Cancer"},{"issue":"15 suppl","key":"10.3816\/CBC.2009.s.008_bib28","first-page":"55s","article-title":"Brain metastases in breast cancer patients: differences in survival depending on biological subtype and RPA RTOG prognostic class","volume":"26","author":"Niwinska","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2009.s.008_bib29","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1002\/cncr.11436","article-title":"Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma","volume":"97","author":"Bendell","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CBC.2009.s.008_bib30","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","article-title":"The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes","volume":"13","author":"Carey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2009.s.008_bib31","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1158\/1078-0432.CCR-04-2421","article-title":"Breast cancer molecular subtypes respond differently to preoperative chemotherapy","volume":"11","author":"Rouzier","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2009.s.008_bib32","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1056\/NEJMoa071167","article-title":"HER2 and response to paclitaxel in nodepositive breast cancer","volume":"357","author":"Hayes","year":"2007","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.3816\/CBC.2009.s.008_bib33","first-page":"S20","article-title":"Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective","volume":"94","author":"Hudis","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2009.s.008_bib34","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nm852","article-title":"Disruption of the Fanconi anemia\u2013BRCA pathway in cisplatin-sensitive ovarian tumors","volume":"9","author":"Taniguchi","year":"2003","journal-title":"Nat Med"},{"key":"10.3816\/CBC.2009.s.008_bib35","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u2018BRCAness\u2019 in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"15 suppl","key":"10.3816\/CBC.2009.s.008_bib36","first-page":"43s","article-title":"TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer","volume":"26","author":"Carey","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.3816\/CBC.2009.s.008_bib37","first-page":"S149","article-title":"Neo-adjuvant cisplatin (CDDP) in \u201ctriple-negative\u201d breast cancer (BC)","volume":"100","author":"Garber","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 1","key":"10.3816\/CBC.2009.s.008_bib38","first-page":"S32","article-title":"Preliminary results of a randomized phase II study of weekly irinotecan\/carboplatin with or without cetuximab in patients with metastatic breast cancer","volume":"106","author":"O'Shaughnessy","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl","key":"10.3816\/CBC.2009.s.008_bib39","first-page":"194s","article-title":"Triple negative breast cancer: a phase 2, multi-center, open-label, randomized trial of gemcitabine\/carboplatin (G\/C), with or without BSI-201, a PARP inhibitor","volume":"69","author":"O'Shaughnessy","year":"2009","journal-title":"Cancer Res"},{"key":"10.3816\/CBC.2009.s.008_bib40","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1097\/01.LAB.0000038508.86221.B3","article-title":"Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis","volume":"82","author":"Korsching","year":"2002","journal-title":"Lab Invest"},{"key":"10.3816\/CBC.2009.s.008_bib41","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/1471-2407-6-276","article-title":"Gene expression patterns associated with p53 status in breast cancer","volume":"6","author":"Troester","year":"2006","journal-title":"BMC Cancer"},{"key":"10.3816\/CBC.2009.s.008_bib42","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1172\/JCI25888","article-title":"\u03b1B-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer","volume":"116","author":"Moyano","year":"2006","journal-title":"J Clin Invest"},{"issue":"suppl","key":"10.3816\/CBC.2009.s.008_bib43","first-page":"70s","article-title":"GRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer","volume":"69","author":"Sparano","year":"2009","journal-title":"Cancer Res"},{"key":"10.3816\/CBC.2009.s.008_bib44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1023\/A:1026146524737","article-title":"A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor \u03b1 (ER) in ER negative human breast cancer cells in combination with 5-aza 2\u2032-deoxycytidine","volume":"81","author":"Keen","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2009.s.008_bib45","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"issue":"15 suppl","key":"10.3816\/CBC.2009.s.008_bib46","first-page":"1008s","article-title":"Randomised, double-blind, placebo-controlled, phase III study of bevacizumab (BV) with docetaxel (D) or docetaxel with placebo (PL) as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO","volume":"26","author":"Miles","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"10.3816\/CBC.2009.s.008_bib47","first-page":"172s","article-title":"First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors","volume":"26","author":"Kopetz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"10.3816\/CBC.2009.s.008_bib48","first-page":"172s","article-title":"A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors","volume":"26","author":"Mahany","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.3816\/CBC.2009.s.008_bib49","first-page":"242s","article-title":"Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059","volume":"69","author":"Finn","year":"2009","journal-title":"Cancer Res"},{"issue":"suppl 1","key":"10.3816\/CBC.2009.s.008_bib50","first-page":"S117","article-title":"Phase II trial of the HDAC inhibitor, vorinostat, in combination with tamoxifen for patients with advanced breast cancer who have failed prior anti-hormonal therapy","volume":"106","author":"Lacevic","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2009.s.008_bib51","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2009.s.008_bib52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.phrs.2005.02.010","article-title":"Chemopotentiation by PARP inhibitors in cancer therapy","volume":"52","author":"Tentori","year":"2005","journal-title":"Pharmacol Res"},{"key":"10.3816\/CBC.2009.s.008_bib53","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [published erratum in: Nature 2007; 447:346]","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.3816\/CBC.2009.s.008_bib54","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.3816\/CBC.2009.s.008_bib55","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1158\/0008-5472.CAN-03-2970","article-title":"The prognostic implication of the basal-like (cyclin Ehigh\/p27low\/p53+\/glomeruloid-microvascularproliferation+) phenotype of BRCA1-related breast cancer","volume":"64","author":"Foulkes","year":"2004","journal-title":"Cancer Res"},{"issue":"suppl","key":"10.3816\/CBC.2009.s.008_bib56","first-page":"793s","article-title":"Efficacy of BSI-201 a poly (ADP-ribose) polymerase-1 (PARP) inhibitor, in combination with gemcitabine\/carboplatin (G\/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial","volume":"27","author":"O'Shaughnessy","year":"2009","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.3816\/CBC.2009.s.008_bib57","first-page":"S32","article-title":"TBCRC 001: EGFR inhibition with cetuximab in metastatic triple negative (basal-like) breast cancer","volume":"106","author":"Carey","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 1","key":"10.3816\/CBC.2009.s.008_bib58","first-page":"S117","article-title":"HDAC inhibitors sensitize ER negative breast cancer cells to AIs","volume":"106","author":"Sabnis","year":"2007","journal-title":"Breast Cancer Res Treat"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911706899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911706899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:10:12Z","timestamp":1761513012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911706899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":58,"alternative-id":["S1526820911706899"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2009.s.008","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2009.s.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}